Cargando…
Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome
BACKGROUND: Peripheral blood-derived inflammation-based markers, such as Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Fibrinogen have been identified as prognostic markers in various solid malignancies. Here we aimed to investigate the prognostic and diagnostic impac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955144/ https://www.ncbi.nlm.nih.gov/pubmed/29774108 http://dx.doi.org/10.18632/oncotarget.25076 |
_version_ | 1783323652486332416 |
---|---|
author | Janik, Stefan Raunegger, Thomas Hacker, Philipp Ghanim, Bahil Einwallner, Elisa Müllauer, Leonhard Schiefer, Ana-Iris Moser, Julia Klepetko, Walter Ankersmit, Hendrik Jan Moser, Bernhard |
author_facet | Janik, Stefan Raunegger, Thomas Hacker, Philipp Ghanim, Bahil Einwallner, Elisa Müllauer, Leonhard Schiefer, Ana-Iris Moser, Julia Klepetko, Walter Ankersmit, Hendrik Jan Moser, Bernhard |
author_sort | Janik, Stefan |
collection | PubMed |
description | BACKGROUND: Peripheral blood-derived inflammation-based markers, such as Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Fibrinogen have been identified as prognostic markers in various solid malignancies. Here we aimed to investigate the prognostic and diagnostic impact of NLR, PLR, and Fibrinogen in patients with thymic epithelial tumors (TETs). RESULTS: Pretreatment Fibrinogen serum concentrations, NLRs and PLRs were highest in patients with TCs and advanced tumor stages. High pretreatment Fibrinogen serum concentration (≥452.5 mg/dL) was significantly associated with worse cause specific survival (CSS; p = 0.001) and freedom from recurrence (FFR; p = 0.043), high NLR (≥4.0) with worse FFR (p = 0.008), and high PLR (≥136.5) with worse CSS (p = 0.032). Longitudinal analysis revealed that compared to patients without tumor recurrence, patients with tumor recurrence had significantly higher NLR (11.8 ± 4.0 vs. 4.70 ± 0.5; p = 0.001) and PLR (410.8 ± 149.1 vs. 228.3 ± 23.7; p = 0.031). CONCLUSION: Overall, Fibrinogen serum concentrations, NLRs, and PLRs were associated with higher tumor stage, more aggressive tumor behavior, recurrence, and worse outcome. Prospective multicenter studies of the diagnostic and prognostic potential of Fibrinogen, NLR, and PLR are warranted. METHODS: This retrospective analysis included 122 patients with TETs who underwent surgical resection between 1999-2015. Fibrinogen serum concentrations, NLRs, and PLRs were measured in patients preoperatively, postoperatively, and later during follow-up. These markers were analyzed for association with several clinical variables, including tumor stage, tumor subtype, FFR, and CSS and to evaluate their prognostic and diagnostic impact for detecting tumor recurrence. |
format | Online Article Text |
id | pubmed-5955144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59551442018-05-17 Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome Janik, Stefan Raunegger, Thomas Hacker, Philipp Ghanim, Bahil Einwallner, Elisa Müllauer, Leonhard Schiefer, Ana-Iris Moser, Julia Klepetko, Walter Ankersmit, Hendrik Jan Moser, Bernhard Oncotarget Research Paper BACKGROUND: Peripheral blood-derived inflammation-based markers, such as Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Fibrinogen have been identified as prognostic markers in various solid malignancies. Here we aimed to investigate the prognostic and diagnostic impact of NLR, PLR, and Fibrinogen in patients with thymic epithelial tumors (TETs). RESULTS: Pretreatment Fibrinogen serum concentrations, NLRs and PLRs were highest in patients with TCs and advanced tumor stages. High pretreatment Fibrinogen serum concentration (≥452.5 mg/dL) was significantly associated with worse cause specific survival (CSS; p = 0.001) and freedom from recurrence (FFR; p = 0.043), high NLR (≥4.0) with worse FFR (p = 0.008), and high PLR (≥136.5) with worse CSS (p = 0.032). Longitudinal analysis revealed that compared to patients without tumor recurrence, patients with tumor recurrence had significantly higher NLR (11.8 ± 4.0 vs. 4.70 ± 0.5; p = 0.001) and PLR (410.8 ± 149.1 vs. 228.3 ± 23.7; p = 0.031). CONCLUSION: Overall, Fibrinogen serum concentrations, NLRs, and PLRs were associated with higher tumor stage, more aggressive tumor behavior, recurrence, and worse outcome. Prospective multicenter studies of the diagnostic and prognostic potential of Fibrinogen, NLR, and PLR are warranted. METHODS: This retrospective analysis included 122 patients with TETs who underwent surgical resection between 1999-2015. Fibrinogen serum concentrations, NLRs, and PLRs were measured in patients preoperatively, postoperatively, and later during follow-up. These markers were analyzed for association with several clinical variables, including tumor stage, tumor subtype, FFR, and CSS and to evaluate their prognostic and diagnostic impact for detecting tumor recurrence. Impact Journals LLC 2018-04-24 /pmc/articles/PMC5955144/ /pubmed/29774108 http://dx.doi.org/10.18632/oncotarget.25076 Text en Copyright: © 2018 Janik et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Janik, Stefan Raunegger, Thomas Hacker, Philipp Ghanim, Bahil Einwallner, Elisa Müllauer, Leonhard Schiefer, Ana-Iris Moser, Julia Klepetko, Walter Ankersmit, Hendrik Jan Moser, Bernhard Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title_full | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title_fullStr | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title_full_unstemmed | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title_short | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
title_sort | prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955144/ https://www.ncbi.nlm.nih.gov/pubmed/29774108 http://dx.doi.org/10.18632/oncotarget.25076 |
work_keys_str_mv | AT janikstefan prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT rauneggerthomas prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT hackerphilipp prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT ghanimbahil prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT einwallnerelisa prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT mullauerleonhard prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT schieferanairis prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT moserjulia prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT klepetkowalter prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT ankersmithendrikjan prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome AT moserbernhard prognosticanddiagnosticimpactoffibrinogenneutrophiltolymphocyteratioandplatelettolymphocyteratioonthymicepithelialtumorsoutcome |